Navigation Links
Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
Date:11/6/2009

--------- --------- --------- -------- Mean FPG at baseline (mg/dL) 161.2 170.5 171.8 145.1 --------------------------- ----- ----- ----- ----- Mean FPG at end of treatment (mg/dL) 155.6 139.4 129.8 116.3 ---------------------------- ----- ----- ----- ----- Change from baseline (mg/dL) -5.6 -31.1* -42.0* -28.8* --------------------------- ---- -------- -------- ------- Change in 2-hr PPG at end of treatment (mg/dL) -16.3 -34.7* -47.1* -69.6* ------------------------- ----- -------- -------- ------- *p = < 0.05

Substantial decreases in FPG and PPG were observed throughout treatment. Decreases in FPG were evident within 24 hours after initiation of treatment, suggesting a rapid and consistent achievement of desired exenatide levels with DUROS delivery. Changes in PPG measured at days 15 and 29 also showed consistent dose-dependent reductions. Changes from baseline in FPG and PPG were statistically significant for the 20 mcg/day, 40 mcg/day and 80 mcg/day doses.

    HbA1c & Body Weight           ITCA 650 Dose Arms (continuous daily dose)
                                  -----------------------------------------
                                     10          20          40        80
                                   mcg/day     mcg/day     mcg/day   mcg/day
                                 ---------   ---------   --------- --------
    % HbA1c at baseline              7.67        7.90        7.45     7.38
    -------------------              ----        ----        ----     ----
    % HbA1c at end of treatment      7.15        7.28        7.00     6.80
    ---------------------------      ----        ----        ----     ----
    Change from baseline            -0.54*      -0.62*      -0.45*   -0.73*
    ----
'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
2. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
3. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
4. Intarcia Therapeutics, Inc. Announces Acceptance of ITCA 650 Phase 1b Study for Late-Breaker Presentation at the American Diabetes Association 69th Scientific Sessions
5. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
6. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
7. Oxygen Biotherapeutics, Inc. Expands Board of Directors
8. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
9. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
10. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
11. Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... diagnostics company that develops and commercializes proprietary technologies ... announced that it has received approval from the ... 5,126,044 outstanding common share purchase warrants ("the Warrants") ... with the Company,s May 2013 private placement financing. ...
(Date:4/17/2015)... 17, 2015 Global Stem Cells ... Stem Cell Summit 2015 April 27 - 29, 2015 ... developments in all areas of stem cell research including ... cells and regenerative medicine. , The conference will ... well as translational research in stem cell therapies, regenerative ...
(Date:4/16/2015)... South Carolina (PRWEB) April 17, 2015 ... and steam system services, released their newly designed, ... The customer facing website effectively promotes the ... , All the information that a site ... steam system services, company capabilities, industries serviced, the ...
(Date:4/16/2015)... South San Francisco, CA (PRWEB) April 16, 2015 ... it is scheduled to report first quarter results on ... Following the announcement, Cytokinetics’ senior management will host a ... operational and financial results and the company’s outlook for ... webcast and can be accessed from the homepage and ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3Spirax Sarco website has a new look 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... 8 LifeNet Health, a leading allograft bio-implant company, ... Tendon, both offering new options for ligament reconstruction. ... new bio-medical implants offer sports medicine physicians another alternative ... Tendon can be used in the reconstruction of either ...
... Dec. 8 Building on its flagship,suite of ... the Pyxis(R) MedStation(R) 4000 and an industry-first Performance,Analytics ... help improve medication safety. , ... medication dispensing system,offers new features that can help ...
... in B-Precursor Acute Lymphoblastic Leukemia Show that Blinatumomab is ... , BETHESDA, Md., Dec. 8 ... company developing novel, proprietary antibodies for the treatment of ... data from a phase 2 clinical trial of BiTE(R) ...
Cached Biology Technology:LifeNet Health Introduces New Sports Medicine Bio-Implants 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 2Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 3Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 4Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias 5
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... March 23, 2015 SoundView Technology Group issues a ... NXTD ) Wocket smart wallet. SoundView was one of the ... their experience with the Wocket in multiple scenarios and outlets. ... Foods and other retailers, making both debit and credit card ... also says, "If the company meets their plans in 2015, ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... work and scientific adventure, marine explorers from more than ... Laboratory (MBL), today delivered the first global Census of ... and hides in the world,s oceans. In one of ... scientists spent over 9,000 days at sea on more ...
... survived for more than 400 million years, the horseshoe ... overharvest and habitat destruction. However, climatic changes may,also play ... how sensitive horseshoe crab populations are to natural climate ... Molecular Ecology . The horseshoe crab is ...
... Jerusalem, October 4, 2010 Researchers at the Hebrew University ... body that play a key role in controlling bone density, ... drug for prevention and treatment of osteoporosis and other bone ... researchers have just been published in the American journal ...
Cached Biology News:MBL scientists reveal findings of World Ocean Microbe Census 2MBL scientists reveal findings of World Ocean Microbe Census 3Climate change affects horseshoe crab numbers 2Hebrew University research holds promise for development of new osteoporosis drug 2
... an internal standard for the quantification of ... 5-OxoETE is a polyunsaturated keto acid formed ... neutrophils. It stimulates cytosolic calcium levels in ... 5-OxoETE selectively stimulates the migration and degranulation ...
... a 10.0 kb Autographa californica (AcNPV) polyhedrin ... AcNPV polyhedrin promoter and two AcNPV p10 ... a Sma I cloning site, followed by ... inverted polyhedrin promoter has been inserted containing ...
BD BioCoat Osteologic Coverslips that have been sterilized by ETO gas. Coating : Osteologic&trade ,Thickness : 0.16 mm ,Diameter : 12.7 mm ,Gridded : No ...
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Biology Products: